Turning on Tregs

How Delinia is threading the IL-2 needle in autoimmunity

Although expanding Tregs to treat autoimmune diseases offers a safer alternative to general immunosuppression, the challenge has been to target only those cells, and avoid stimulating T cells that will exacerbate disease. By homing in a form of the IL-2 receptor only on Tregs, Delinia Inc. has carved a way to potentiate the suppressive pathway alone.

Delinia was launched earlier this year to develop

Read the full 633 word article

User Sign In